公开(公告)号：US12195746B2

公开(公告)日：2025-01-14

申请号：US17706522

申请日：2022-03-28

Applicant: Combined Therapeutics, Inc.

Inventor： Romain Micol

IPC: C12N15/86 ,  A61K31/7088 ,  A61K35/763 ,  A61K45/06 ,  A61K48/00

Abstract: A composition for expressing a polypeptide within a target organ including a delivery particle, and at least a first mRNA sequence complexed with, encapsulated by, or otherwise associated with the delivery particle. The mRNA sequence includes a coding sequence which codes for the polypeptide, at least a first untranslated region (UTR) sequence, and at least one micro-RNA (miRNA) binding site sequence, wherein the miRNA binding site sequence is located within, immediately 5′ to, or immediately 3′ to, the first UTR sequence. The miRNA binding site sequence is selected so as to provide for differential expression of the coding sequence between first and second cell types comprised within the target organ. Methods for making and using the composition are provided, particularly in treatment of disease, such as cancer.

公开(公告)号：US20240374663A1

公开(公告)日：2024-11-14

申请号：US18690101

申请日：2022-10-12

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： Gregory Friedman ,  James Markert ,  George Yancey Gillespie ,  Joshua Bernstock ,  Kyung-Don Kang

IPC: A61K35/763 ,  A61K9/00 ,  A61K31/713 ,  A61K38/21 ,  A61P35/00

Abstract: A method of treating a central nervous system cancer in a subject comprising administering to the subject a preconditioning agent, and, administering to the subject a therapeutic dose of an oncolytic virus; wherein the preconditioning agent is an immunostimulant selected from the group consisting of a toll-like receptor agonist, a subtherapeutic dose of an oncolytic virus, and/or an interferon that induces a transient anti-viral response and/or upregulates an interferon response; and wherein the preconditioning agent and the therapeutic dose of the oncolytic virus is administered to the subject's cerebrospinal fluid or periependymal region. Provided herein are methods of treating a central nervous system cancer in a subject. This method allows for intrathecal administration of oncolytic virus, which, until the present invention, resulted in unacceptable toxicity.

公开(公告)号：US12128098B2

公开(公告)日：2024-10-29

申请号：US17160776

申请日：2021-01-28

Applicant: Squarex, LLC

Inventor： Hugh McTavish

IPC: A61K39/245 ,  A61K9/00 ,  A61K31/04 ,  A61K31/122 ,  A61K31/215 ,  A61K35/763 ,  A61K39/12 ,  A61K39/165 ,  C07K14/035 ,  G01N33/571 ,  A61K39/00

CPC classification number: A61K39/245 ,  A61K9/0014 ,  A61K9/0021 ,  A61K31/04 ,  A61K31/122 ,  A61K31/215 ,  A61K35/763 ,  A61K39/12 ,  A61K39/165 ,  C07K14/035 ,  G01N33/571 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55511 ,  C12N2710/16611 ,  A61K31/122 ,  A61K2300/00 ,  A61K31/04 ,  A61K2300/00 ,  A61K31/215 ,  A61K2300/00

Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site other than at the site of an HSV lesion to induce a DTH response during one or more outbreaks of the HSV infection. The method reduces the number of HSV outbreaks in persons experiencing outbreaks.

公开(公告)号：US12036256B2

公开(公告)日：2024-07-16

申请号：US17046466

申请日：2019-04-12

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： James Brian Rottman

IPC: A61K35/763 ,  A61K39/00 ,  A61K39/12 ,  A61K39/285 ,  A61K39/39 ,  A61P35/00 ,  C07K14/725 ,  C12N7/00

CPC classification number: A61K35/763 ,  A61K39/001102 ,  A61K39/001112 ,  A61P35/00 ,  C07K14/7051 ,  C12N7/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/5256 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2710/16621 ,  C12N2710/16632

Abstract: The invention provides improved compositions and methods for the treatment of solid cancers.

公开(公告)号：US11918660B2

公开(公告)日：2024-03-05

申请号：US18180791

申请日：2023-03-08

Applicant: Krystal Biotech, Inc.

Inventor： Suma Krishnan ,  Trevor Parry ,  Dana Michelle Previte ,  Mary Jane Duermeyer

IPC: C12N15/869 ,  A61K35/763 ,  A61K38/19 ,  A61K38/20 ,  A61K48/00 ,  A61P35/00 ,  C12N7/00 ,  C12N15/24 ,  C12N15/26 ,  C12N15/86

CPC classification number: A61K48/0066 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/208 ,  A61P35/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16622 ,  C12N2710/16633 ,  C12N2710/16643 ,  C12N2710/16662 ,  C12N2710/16671

Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.

公开(公告)号：US11865148B2

公开(公告)日：2024-01-09

申请号：US18060515

申请日：2022-11-30

Applicant: Krystal Biotech, Inc.

Inventor： Suma Krishnan

IPC: A61K35/763 ,  A61K9/00 ,  A61K38/17 ,  A61K38/39 ,  A61K48/00 ,  C07K14/78 ,  C12N9/02 ,  A61K9/06 ,  A61K47/38

CPC classification number: A61K35/763 ,  A61K9/0014 ,  A61K38/1748 ,  A61K38/39 ,  A61K48/005 ,  C07K14/78 ,  C12N9/0071 ,  C12Y114/11004 ,  A61K9/06 ,  A61K47/38 ,  C12N2710/16643 ,  A61K39/12 ,  A61K2039/53 ,  C12N15/86 ,  C12N7/00 ,  C12N2710/16034 ,  A61K38/39

Abstract: Provided herein are methods of delivering transgenes to an eye of a subject comprising the use of pharmaceutical compositions having one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of the transgene in the eye. Also provided herein are methods of correcting vision loss in a subject in need thereof comprising the use of the pharmaceutical compositions described herein.

公开(公告)号：US20230372472A1

公开(公告)日：2023-11-23

申请号：US18028139

申请日：2021-09-24

Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  DANA-FARBER CANCER INSTITUTE, INC.

Inventor： David M. KNIPE ,  Michael J. WALSH ,  Stephanie K. DOUGAN

IPC: A61K39/245 ,  C12N7/00 ,  A61K35/763 ,  A61K38/20 ,  A61P35/00

CPC classification number: A61K39/245 ,  C12N7/00 ,  A61K35/763 ,  A61K38/208 ,  A61P35/00 ,  C12N2710/16621 ,  C12N2710/16632 ,  C12N2710/16671 ,  A61K2039/572

Abstract: Provided herein is a replication-defective oncolytic herpes simplex virus 1 (HSV-1) recombinant virus, comprising within its genome: a coding sequence encoding a fusion protein.

公开(公告)号：US11786569B2

公开(公告)日：2023-10-17

申请号：US16959025

申请日：2019-01-28

Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education

Inventor： Greg M. Delgoffe ,  Dayana Rivadeneira ,  Padmavathi Sampath ,  Stephen H. Thorne

IPC: A61K38/00 ,  A61K35/763 ,  A61P35/00 ,  A61K35/768 ,  C07K14/495 ,  C07K14/54 ,  C07K14/545 ,  C07K14/55 ,  C07K14/56 ,  C07K14/57 ,  C07K14/575 ,  C12N7/00 ,  A61K45/06

CPC classification number: A61K35/763 ,  A61K35/768 ,  A61P35/00 ,  C07K14/495 ,  C07K14/545 ,  C07K14/5406 ,  C07K14/5418 ,  C07K14/5425 ,  C07K14/5428 ,  C07K14/5437 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/56 ,  C07K14/57 ,  C07K14/5759 ,  C12N7/00 ,  A61K45/06

Abstract: Recombinant oncolytic viruses (OVs) that express one or more metabolic modulator proteins, such as an adipokine (e.g., leptin or chemerin), insulin, and/or IGF-1, and methods of their use to treat cancer, for example in immunotherapy anti-cancer treatments. In some examples, such recombinant OVs and methods increase T cell infiltration into the tumor or tumor microenvironment.

公开(公告)号：US11779660B2

公开(公告)日：2023-10-10

申请号：US17711947

申请日：2022-04-01

Applicant: Krystal Biotech, Inc.

Inventor： Suma Krishnan ,  Trevor Parry ,  Dana Michelle Previte ,  Mary Jane Duermeyer

IPC: A61K35/763 ,  A61K48/00 ,  A61K38/19 ,  A61P35/00 ,  C12N7/00 ,  C12N15/24 ,  A61K38/20 ,  C12N15/86

CPC classification number: A61K48/0066 ,  A61K38/193 ,  A61K38/208 ,  A61K38/2013 ,  A61P35/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16622 ,  C12N2710/16633 ,  C12N2710/16643 ,  C12N2710/16662 ,  C12N2710/16671

Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.

公开(公告)号：US20230241140A1

公开(公告)日：2023-08-03

申请号：US18165770

申请日：2023-02-07

Applicant: Oncorus, Inc.

Inventor： Mitchell H. FINER ,  Lorena LERNER ,  Christophe QUÉVA ,  Edward KENNEDY

IPC: A61K35/763 ,  C12N7/00 ,  C12N15/86

CPC classification number: A61K35/763 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16632 ,  C12N2710/16643

Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.